Abstract

BackgroundPlacenta-derived MSCs (P-MSCs) represent a promising tool for cell-based therapeutic applications. However, the increasing demand for P-MSCs in clinical trials makes high quality and large number of P-MSCs mandatory. Here, we aim to develop an efficient protocol for P-MSC isolation and culture.MethodsThe modified explant culture (MEC) method by combining an initial mild enzymatic reaction with the subsequent explant culture was developed to simultaneously produce various P-MSCs from the different regions of the placenta in serum-free medium (SFM). Its isolation efficiencies, cell yield, and proliferative capacity were compared with the conventional explant culture (EC) method. Furthermore, we determined whether functional properties of P-MSCs are affected by the used tissue-harvesting sites in terms of their proliferation, migration, and the immunomodulatory effect on macrophage.ResultsThe MEC method achieved higher yield and shorter time in primary cell confluence in SFM compared with the conventional method. The harvested cells possessed the MSC characteristics and demonstrated significantly stronger proliferation ability. Importantly, MSCs derived from chorionic plate (CP-MSCs) were found to exhibit superior properties to the other P-MSCs in proliferation and migration capacity, maintaining the fetal origin over serial passages. Notably, CP-MSCs show stronger ability in regulating macrophage polarization from M1 to M2.ConclusionOur study developed an efficient and high-yield technique to produce high-quality P-MSCs from the placenta, hence serving as an optimal source of MSCs for clinical application.

Highlights

  • Placenta-derived Mesenchymal stem cells (MSCs) (P-MSCs) represent a promising tool for cell-based therapeutic applications

  • Chorionic plate-derived (CP)-MSCs and umbilical cord-derived MSCs (UCMSCs) were taken as representative examples for the comparison of MSC isolate methods

  • At day 4, rod-like and irregularly shaped cells were observed to migrate from the CP and Umbilical cord-derived (UC) tissue in the modified explant culture (MEC) group while no cells were detected in the explant culture (EC) group

Read more

Summary

Introduction

Placenta-derived MSCs (P-MSCs) represent a promising tool for cell-based therapeutic applications. A recent study found that P-MSCs possess better immunoregulatory properties compared to UC-MSCs [15] It seems that the placenta is the better choice for obtaining MSCs. Currently, various kinds of P-MSCs have been successively isolated from different anatomical regions of the placenta, including chorionic plate-derived MSCs (CP-MSCs), chorionic villiderived MSCs (CV-MSCs), amniotic membrane-derived MSCs (AM-MSCs), and decidua-derived MSCs (D-MSCs). As reported in the literature, the current cultured P-MSCs are usually confounded by maternal cell contamination [16,17,18] The reason behind this phenomenon is complicated, like the variation in MSCs obtained from different regions of the placenta, culture system, and so on. It is mandatory to define the key parameters to obtain high-quality MSCs like as pure fetal P-MSCs for clinical trials

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.